<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00700063</url>
  </required_header>
  <id_info>
    <org_study_id>PEP005-015</org_study_id>
    <nct_id>NCT00700063</nct_id>
  </id_info>
  <brief_title>A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of 0.005%, 0.01% and 0.015% PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peplin</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peplin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase IIb study is designed to assess the safety and efficacy of 0.005%, 0.01% and
      0.015% PEP005 Topical Gel when applied to an area of skin, containing 4-8 AK lesions on the
      face or scalp.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of AEs Recorded Throughout the Study</measure>
    <time_frame>57 days</time_frame>
    <description>Incidence of AEs recorded throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SAE Recorded Throughout the Study</measure>
    <time_frame>57 days</time_frame>
    <description>Incidence of SAE recorded throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate and Severity of LSRs Following Study Medication Application</measure>
    <time_frame>Baseline</time_frame>
    <description>The treatment area was assessed at baseline, Day 1 (pre-dose), and at each subsequent study visit for the presence and grade (0 to 4) of the following LSRs: erythema; flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. A composite LSR score (0 to 24), reflecting the sum of each individual LSR grade, was calculated for each patient at each visit.
The actual value and change from baseline in the composite LSR score were also summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence Rate and Severity of LSRs Following Study Medication Application</measure>
    <time_frame>Day 57</time_frame>
    <description>The treatment area was assessed at baseline, Day 1 (pre-dose), and at each subsequent study visit for the presence and grade (0 to 4) of the following LSRs: erythema; flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. A composite LSR score (0 to 24), reflecting the sum of each individual LSR grade, was calculated for each patient at each visit.
The actual value and change from baseline in the composite LSR score were also summarized.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Hyperpigmentation Following Study Medication Application</measure>
    <time_frame>Baseline</time_frame>
    <description>The selected treatment area was assessed for hyperpigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Hyperpigmentation Following Study Medication Application</measure>
    <time_frame>Day 57</time_frame>
    <description>The selected treatment area was assessed for hyperpigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Hypopigmentation Following Study Medication Application</measure>
    <time_frame>Baseline</time_frame>
    <description>The selected treatment area was assessed for hypopigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Hypopigmentation Following Study Medication Application</measure>
    <time_frame>Day 57</time_frame>
    <description>The selected treatment area was assessed for hypopigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Scarring Following Study Medication Application</measure>
    <time_frame>Baseline</time_frame>
    <description>The selected treatment area was assessed for scarring at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any scarring was present, the significance and extent of scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Scarring Following Study Medication Application</measure>
    <time_frame>Day 57</time_frame>
    <description>The selected treatment area was assessed for scarring at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any scarring was present, the significance and extent of scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Clearance Rate of AK Lesions;</measure>
    <time_frame>Day 57</time_frame>
    <description>Defined as the number of patients at the day 57 post-treatment visit with no clinically visible AK lesions in the selected treatment area</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy (Clearance of AK Lesions) Partial Clearance Rate</measure>
    <time_frame>57 days</time_frame>
    <description>Partial clearence rate, defined as the number of patients at the Day 57 visit with a 75% or greater reduction in the number of AK lesions identified at baseline, in the Face and Scalp</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">265</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 Topical Gel</intervention_name>
    <description>0.005%, two days treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 Topical Gel</intervention_name>
    <description>0.01%, two days treatment</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 Topical Gel</intervention_name>
    <description>0.015%, two days treatment</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle gel</intervention_name>
    <description>two days treatment</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 Topical Gel</intervention_name>
    <description>0.005%, three days treatment</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 Topical Gel</intervention_name>
    <description>0.01%, three days treatment</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEP005 Topical Gel</intervention_name>
    <description>0.015%, three days treatment</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle gel</intervention_name>
    <description>three days treatment</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be male or female

          -  Female patients must be of

               -  Non-childbearing potential;

               -  Childbearing potential, provided negative pregnancy test and using effective
                  contraception

          -  4 to 8 AK lesions on the face or scalp

        Exclusion Criteria:

          -  Cosmetic or therapeutic procedures within 2 weeks and within 2 cm of the selected
             treatment area.

          -  Treatment with immunomodulators, or interferon/ interferon inducers or systemic
             medications that suppress the immune system: within 4 weeks.

          -  Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy:

        within 8 weeks and 2 cm of treatment area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Burke Pharmaceutical Research</name>
      <address>
        <city>Hot Springs</city>
        <state>Arizona</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research of Arkansas</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Koppel Dermatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research Group Inc</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Surgery Medical Group Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>470 Castro St Suite 202-204</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solano Clinical Research</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists Inc</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spencer Derm and Skin Surgery Center</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Trial</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Clinic</name>
      <address>
        <city>Champaign</city>
        <state>Illinois</state>
        <zip>61820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TKL Research, Inc.</name>
      <address>
        <city>Paramus</city>
        <state>New Jersey</state>
        <zip>07652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Institute of Dermatology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc. 8140 N. MoPac, Bldg. 3, Suite 120,</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce and Associates, The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates of Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southderm Pty Ltd</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Centre</name>
      <address>
        <city>Benowa</city>
        <state>Queensland</state>
        <zip>4217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siller Medical</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/</url>
    <description>Food and Drug Authority</description>
  </link>
  <link>
    <url>http://www.tga.gov.au/</url>
    <description>Therapeutic Goods Administration</description>
  </link>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>July 18, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2012</results_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peplin</keyword>
  <keyword>Actinic keratosis</keyword>
  <keyword>PEP005</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient randomized: 24 June 2008 Last patient completed Day 57: 20 October 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1. PEP005 Topical Gel 0.005%</title>
          <description>Two days treatment day 1, 2</description>
        </group>
        <group group_id="P2">
          <title>2. PEP005 Topical Gel 0.01%</title>
          <description>Two days treatment, day 1, 2</description>
        </group>
        <group group_id="P3">
          <title>3. PEP005 Topical Gel 0.015%</title>
          <description>Two days treatment day 1, 2</description>
        </group>
        <group group_id="P4">
          <title>4. Vehicle Gel</title>
          <description>Two days treatment, day 1, 2</description>
        </group>
        <group group_id="P5">
          <title>5. PEP005 Topical Gel 0.005%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="P6">
          <title>6. PEP005 Topical Gel 0.01%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="P7">
          <title>7. PEP005 Topical Gel 0.015%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="P8">
          <title>8. Vehicle Gel</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="33"/>
                <participants group_id="P5" count="33"/>
                <participants group_id="P6" count="34"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="33"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="31"/>
                <participants group_id="P6" count="34"/>
                <participants group_id="P7" count="32"/>
                <participants group_id="P8" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1. PEP005 Topical Gel 0.005%</title>
          <description>Two days treatment day 1, 2</description>
        </group>
        <group group_id="B2">
          <title>2. PEP005 Topical Gel 0.01%</title>
          <description>Two days treatment, day 1, 2</description>
        </group>
        <group group_id="B3">
          <title>3. PEP005 Topical Gel 0.015%</title>
          <description>Two days treatment day 1, 2</description>
        </group>
        <group group_id="B4">
          <title>4. Vehicle Gel</title>
          <description>Two days treatment, day 1, 2</description>
        </group>
        <group group_id="B5">
          <title>5. PEP005 Topical Gel 0.005%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="B6">
          <title>6. PEP005 Topical Gel 0.01%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="B7">
          <title>7. PEP005 Topical Gel 0.015%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="B8">
          <title>8. Vehicle Gel</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="33"/>
            <count group_id="B5" value="33"/>
            <count group_id="B6" value="34"/>
            <count group_id="B7" value="32"/>
            <count group_id="B8" value="33"/>
            <count group_id="B9" value="265"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="11"/>
                    <measurement group_id="B9" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="18"/>
                    <measurement group_id="B8" value="22"/>
                    <measurement group_id="B9" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="10.2"/>
                    <measurement group_id="B2" value="67.5" spread="10.5"/>
                    <measurement group_id="B3" value="67.8" spread="7.0"/>
                    <measurement group_id="B4" value="65.2" spread="9.7"/>
                    <measurement group_id="B5" value="68.7" spread="11.0"/>
                    <measurement group_id="B6" value="67.7" spread="9.0"/>
                    <measurement group_id="B7" value="67.2" spread="10.1"/>
                    <measurement group_id="B8" value="69.3" spread="10.7"/>
                    <measurement group_id="B9" value="67.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="29"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of AEs Recorded Throughout the Study</title>
        <description>Incidence of AEs recorded throughout the study</description>
        <time_frame>57 days</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of AEs Recorded Throughout the Study</title>
          <description>Incidence of AEs recorded throughout the study</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="14"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy (Clearance of AK Lesions) Partial Clearance Rate</title>
        <description>Partial clearence rate, defined as the number of patients at the Day 57 visit with a 75% or greater reduction in the number of AK lesions identified at baseline, in the Face and Scalp</description>
        <time_frame>57 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy (Clearance of AK Lesions) Partial Clearance Rate</title>
          <description>Partial clearence rate, defined as the number of patients at the Day 57 visit with a 75% or greater reduction in the number of AK lesions identified at baseline, in the Face and Scalp</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="14"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of SAE Recorded Throughout the Study</title>
        <description>Incidence of SAE recorded throughout the study</description>
        <time_frame>57 days</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of SAE Recorded Throughout the Study</title>
          <description>Incidence of SAE recorded throughout the study</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate and Severity of LSRs Following Study Medication Application</title>
        <description>The treatment area was assessed at baseline, Day 1 (pre-dose), and at each subsequent study visit for the presence and grade (0 to 4) of the following LSRs: erythema; flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. A composite LSR score (0 to 24), reflecting the sum of each individual LSR grade, was calculated for each patient at each visit.
The actual value and change from baseline in the composite LSR score were also summarized.</description>
        <time_frame>Baseline</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate and Severity of LSRs Following Study Medication Application</title>
          <description>The treatment area was assessed at baseline, Day 1 (pre-dose), and at each subsequent study visit for the presence and grade (0 to 4) of the following LSRs: erythema; flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. A composite LSR score (0 to 24), reflecting the sum of each individual LSR grade, was calculated for each patient at each visit.
The actual value and change from baseline in the composite LSR score were also summarized.</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.3"/>
                    <measurement group_id="O2" value="1.6" spread="1.3"/>
                    <measurement group_id="O3" value="1.3" spread="0.9"/>
                    <measurement group_id="O4" value="1.4" spread="1.1"/>
                    <measurement group_id="O5" value="1.6" spread="1.5"/>
                    <measurement group_id="O6" value="1.5" spread="1.3"/>
                    <measurement group_id="O7" value="1.3" spread="1.0"/>
                    <measurement group_id="O8" value="1.7" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence Rate and Severity of LSRs Following Study Medication Application</title>
        <description>The treatment area was assessed at baseline, Day 1 (pre-dose), and at each subsequent study visit for the presence and grade (0 to 4) of the following LSRs: erythema; flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. A composite LSR score (0 to 24), reflecting the sum of each individual LSR grade, was calculated for each patient at each visit.
The actual value and change from baseline in the composite LSR score were also summarized.</description>
        <time_frame>Day 57</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence Rate and Severity of LSRs Following Study Medication Application</title>
          <description>The treatment area was assessed at baseline, Day 1 (pre-dose), and at each subsequent study visit for the presence and grade (0 to 4) of the following LSRs: erythema; flaking/scaling, crusting, swelling, vesiculation/pustulation, and erosion/ulceration. A composite LSR score (0 to 24), reflecting the sum of each individual LSR grade, was calculated for each patient at each visit.
The actual value and change from baseline in the composite LSR score were also summarized.</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.1"/>
                    <measurement group_id="O2" value="1.1" spread="1.0"/>
                    <measurement group_id="O3" value="0.8" spread="0.8"/>
                    <measurement group_id="O4" value="1.3" spread="1.2"/>
                    <measurement group_id="O5" value="1.4" spread="1.4"/>
                    <measurement group_id="O6" value="1.1" spread="1.0"/>
                    <measurement group_id="O7" value="0.8" spread="1.3"/>
                    <measurement group_id="O8" value="1.1" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Hyperpigmentation Following Study Medication Application</title>
        <description>The selected treatment area was assessed for hyperpigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted.</description>
        <time_frame>Baseline</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hyperpigmentation Following Study Medication Application</title>
          <description>The selected treatment area was assessed for hyperpigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted.</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="15"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Hyperpigmentation Following Study Medication Application</title>
        <description>The selected treatment area was assessed for hyperpigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
        <time_frame>Day 57</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hyperpigmentation Following Study Medication Application</title>
          <description>The selected treatment area was assessed for hyperpigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="11"/>
                    <measurement group_id="O7" value="11"/>
                    <measurement group_id="O8" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Hypopigmentation Following Study Medication Application</title>
        <description>The selected treatment area was assessed for hypopigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
        <time_frame>Baseline</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypopigmentation Following Study Medication Application</title>
          <description>The selected treatment area was assessed for hypopigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Hypopigmentation Following Study Medication Application</title>
        <description>The selected treatment area was assessed for hypopigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
        <time_frame>Day 57</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hypopigmentation Following Study Medication Application</title>
          <description>The selected treatment area was assessed for hypopigmentation at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any pigmentation was present, the significance and extent of pigmentation and scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="9"/>
                    <measurement group_id="O7" value="12"/>
                    <measurement group_id="O8" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Scarring Following Study Medication Application</title>
        <description>The selected treatment area was assessed for scarring at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any scarring was present, the significance and extent of scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
        <time_frame>Baseline</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Scarring Following Study Medication Application</title>
          <description>The selected treatment area was assessed for scarring at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any scarring was present, the significance and extent of scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent)</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="10"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Scarring Following Study Medication Application</title>
        <description>The selected treatment area was assessed for scarring at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any scarring was present, the significance and extent of scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent).</description>
        <time_frame>Day 57</time_frame>
        <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Scarring Following Study Medication Application</title>
          <description>The selected treatment area was assessed for scarring at baseline (Day 1 pre-dose), Day 57, and at each poststudy followup visit as warranted. If any scarring was present, the significance and extent of scarring was recorded. At all timepoints, pigmentation evaluations were performed by a board certified Dermatologist (or equivalent).</description>
          <population>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complete Clearance Rate of AK Lesions;</title>
        <description>Defined as the number of patients at the day 57 post-treatment visit with no clinically visible AK lesions in the selected treatment area</description>
        <time_frame>Day 57</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. PEP005 Topical Gel 0.005%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O2">
            <title>2. PEP005 Topical Gel 0.01%</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O3">
            <title>3. PEP005 Topical Gel 0.015%</title>
            <description>Two days treatment day 1, 2</description>
          </group>
          <group group_id="O4">
            <title>4. Vehicle Gel</title>
            <description>Two days treatment, day 1, 2</description>
          </group>
          <group group_id="O5">
            <title>5. PEP005 Topical Gel 0.005%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O6">
            <title>6. PEP005 Topical Gel 0.01%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O7">
            <title>7. PEP005 Topical Gel 0.015%</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
          <group group_id="O8">
            <title>8. Vehicle Gel</title>
            <description>Three days treatment, day 1, 2, 3</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Clearance Rate of AK Lesions;</title>
          <description>Defined as the number of patients at the day 57 post-treatment visit with no clinically visible AK lesions in the selected treatment area</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="33"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="34"/>
                <count group_id="O7" value="32"/>
                <count group_id="O8" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>57 days</time_frame>
      <desc>One patient in the PEP005 Topical Gel 0.005% group received no dose of study medication and were therefore not included in the safety population.</desc>
      <group_list>
        <group group_id="E1">
          <title>1. PEP005 Topical Gel 0.005%</title>
          <description>Two days treatment day 1, 2</description>
        </group>
        <group group_id="E2">
          <title>2. PEP005 Topical Gel 0.01%</title>
          <description>Two days treatment, day 1, 2</description>
        </group>
        <group group_id="E3">
          <title>3. PEP005 Topical Gel 0.015%</title>
          <description>Two days treatment day 1, 2</description>
        </group>
        <group group_id="E4">
          <title>4. Vehicle Gel</title>
          <description>Two days treatment, day 1, 2</description>
        </group>
        <group group_id="E5">
          <title>5. PEP005 Topical Gel 0.005%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="E6">
          <title>6. PEP005 Topical Gel 0.01%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="E7">
          <title>7. PEP005 Topical Gel 0.015%</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
        <group group_id="E8">
          <title>8. Vehicle Gel</title>
          <description>Three days treatment, day 1, 2, 3</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle Strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYELID OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>APPLICATION SITE IRRITATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>APPLICATION SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Institution and Investigator agree not to publish the results of this study without the prior written consent of Sponsor. As used herein, the term 'publish' shall include oral presentations, written abstracts, written manuscripts, etc.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>Leo Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>ctr.disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

